Kalaris Therapeutics CFO granted 235,000 options at $4.99/share

Kalaris Therapeutics (KLRS) reported a Form 4 for CFO Matthew Gall, showing a grant of stock options for 235,000 shares at an exercise price of $4.99 on November 3, 2025.

Accepted by SEC EDGAR 11/03/2025 - 05:25 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Kalaris Therapeutics (KLRS) reported a Form 4 for CFO Matthew Gall, showing a grant of stock options for 235,000 shares at an exercise price of $4.99 on November 3, 2025.

The options expire on November 2, 2035 and vest over four years: 25% on November 3, 2026, then the remainder in equal monthly installments, subject to continuous service. Following the grant, 235,000 derivative securities were beneficially owned directly.

Insider Trade Summary

Grant/Award: 235,000 shares

Grant/Award 1 txn

Insider Gall Matthew

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	235,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 235,000 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on November 3, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on November 3, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did KLRS disclose in this Form 4?

A grant of stock options to CFO Matthew Gall covering 235,000 shares at an exercise price of $4.99 per share on November 3, 2025.

How many options were granted and at what price?

The grant covers 235,000 options with an exercise price of $4.99 per share.

What is the vesting schedule for the options?

Vesting is over four years: 25% on November 3, 2026, with the remainder vesting in equal monthly installments thereafter, subject to continuous service.

When do the options expire?

The options expire on November 2, 2035.

Who is the reporting person and their role at KLRS?

The reporting person is Matthew Gall, the company’s Chief Financial Officer.

What was the ownership form after the transaction?

Ownership was reported as Direct (D) with 235,000 derivative securities beneficially owned following the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gall Matthew

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE SUITE 5500

(Street)

BERKELEY HEIGHTS NJ 07922

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.99	11/03/2025		A		235,000		(1)	11/02/2035	Common Stock	235,000	$0	235,000	D

Explanation of Responses:

1. The option was granted on November 3, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on November 3, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

	/s/ Matthew Gall	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.